A judge yesterday dismissed most of the claims from pharmacy groups that Express Scripts' (ESRX)...


A judge yesterday dismissed most of the claims from pharmacy groups that Express Scripts' (ESRX) $29B acquisition of Medco breaches antitrust law. However, the judge allowed the plaintiffs to replead, and said their claims over clinical specialty drugs can move forward.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs